m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01133)
Name
SB-9200
Synonyms
SB 9200
    Click to Show/Hide
Status
Phase 2
Structure
Formula
C25H34N7O13PS
InChI
1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1
InChIKey
CJCYTUJOSMYXLE-JDLSZIHUSA-N
PubChem CID
24737742
TTD Drug ID
D04HQC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Retinoic acid-inducible gene-1 (RIG-1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for SB-9200. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of SB-9200 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Retinoic acid-inducible gene-1 (RIG-1) is a therapeutic target for SB-9200. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of SB-9200 through regulating the expression of Retinoic acid-inducible gene-1 (RIG-1). [2], [3]
References
Ref 1 N (6)-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling. J Biol Chem. 2020 Sep 11;295(37):13123-13133. doi: 10.1074/jbc.RA120.014260. Epub 2020 Jul 27.
Ref 2 DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 3 METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. Cell Rep. 2021 May 11;35(6):109091. doi: 10.1016/j.celrep.2021.109091. Epub 2021 May 3.